Kavita Aggarwal
Chief Tech/Sci/R&D Officer bij VERONA PHARMA PLC
Profiel
Kavita Aggarwal is a professional with a current job as Senior Vice President-Medical Affairs at Verona Pharma Plc since 2023.
Prior to this, she worked as VP-Global Commercial Pipeline Strategy at BioCryst Pharmaceuticals, Inc. and as Vice President-Medical Affairs at Dova Pharmaceuticals, Inc. Dr. Aggarwal completed her undergraduate degree at North Carolina State University and her doctorate at the University of North Carolina at Chapel Hill.
Actieve functies van Kavita Aggarwal
| Bedrijven | Functie | Begin |
|---|---|---|
| VERONA PHARMA PLC | Chief Tech/Sci/R&D Officer | 01-01-2023 |
Eerdere bekende functies van Kavita Aggarwal
| Bedrijven | Functie | Einde |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| BIOCRYST PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Kavita Aggarwal
| North Carolina State University | Undergraduate Degree |
| University of North Carolina at Chapel Hill | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
